Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis of 14 trials involving 18,558 patients indicates that while GLP-1 receptor agonists significantly improve quality of life, functional capacity, and all-cause mortality in heart failure patients (particularly those with HFpEF and obesity), they did not significantly reduce the composite of cardiovascular death and heart failure hospitalization, with mortality benefits appearing driven by cardiovascular outcomes trial subgroups rather than dedicated heart failure trials.

The Gist

Imagine your heart is a hardworking engine in a car. Sometimes, that engine gets clogged with sludge (heart failure), making it hard to drive. For a long time, mechanics (doctors) had a great toolkit for fixing engines that were running too slowly (low pumping power), but they were stuck when the engine was running fine but still felt heavy and sluggish (heart failure with preserved ejection fraction, or HFpEF), especially if the car was carrying too much extra weight (obesity).

Recently, a new type of fuel additive called GLP-1 Receptor Agonists (drugs like semaglutide and tirzepatide) became famous for helping people lose weight and control their blood sugar. Doctors wondered: Could this additive also help fix the clogged or heavy heart engine?

This paper is a massive "report card" that gathered data from 14 different studies involving nearly 19,000 patients to answer that question. Here is what they found, explained simply:

1. The Main Goal: Stopping the "Double Trouble"

The researchers wanted to know if these drugs could stop the two worst things from happening at once: dying from heart issues or being sent to the hospital for heart failure.

• The Result: It was a "maybe." The drugs showed a trend toward helping (a 14% reduction in risk), but it wasn't quite strong enough to be statistically certain. It's like a runner who finishes just a fraction of a second behind the winner—they were close, but didn't quite cross the finish line first in this specific race.

2. The Big Surprise: Saving Lives

Even though they didn't win the "hospital race" by a clear margin, these drugs were excellent at preventing death from any cause.

• The Analogy: Think of the heart engine as a house. The drugs might not have stopped every leak (hospital visits), but they definitely reinforced the roof so the house didn't collapse (death). The data showed a clear, consistent drop in deaths across all the studies.
• The Catch: This "life-saving" signal came mostly from studies where heart failure was just a side note (people with diabetes who also had heart issues). In the studies where heart failure was the main focus, the results were mixed. One major study actually saw slightly more deaths in the drug group, though it wasn't a huge difference.

3. The Real Win: Feeling Better and Moving More

This is where the drugs truly shined, especially for people with the "heavy engine" type of heart failure (HFpEF) who are also overweight.

• The Analogy: Imagine your heart is a tired hiker carrying a heavy backpack. These drugs didn't just lighten the backpack; they gave the hiker a pair of super-shoes.
• The Evidence:
  • Quality of Life: Patients reported feeling significantly better, like waking up after a good night's sleep instead of a bad one.
  • Walking Distance: Patients could walk about 17 meters (60 feet) further in a 6-minute test. That might not sound like much, but for someone with a failing heart, that's like going from being stuck on the couch to walking all the way to the mailbox without stopping.

4. The "One Size Does Not Fit All" Problem

The researchers found that these drugs work differently depending on who you are and when you take them.

• The "Acute" vs. "Chronic" Mix-up: Most studies looked at people with chronic, long-term heart issues. However, one study (called FIGHT) looked at people who were in the emergency room with a heart attack or sudden heart failure. In that specific group, the drug didn't help and might have even caused trouble.
• The Lesson: It's like trying to use a gardening tool to fix a broken car. If your heart is in a sudden crisis (acute), these drugs might not be the right tool yet. But if your heart is struggling slowly over time (chronic), especially if you carry extra weight, these drugs are like a magic fertilizer.

5. The Weight Factor

These drugs are famous for weight loss, and in these heart studies, patients lost an average of 20 pounds (9 kg).

• The Metaphor: Imagine the heart is a person trying to run a marathon while wearing a heavy winter coat. These drugs helped take off the coat. It's hard to tell if the heart got better because the drug fixed the engine directly, or just because the engine didn't have to work as hard carrying the extra weight. Both are good news!

The Bottom Line

• For Heart Failure with Obesity (HFpEF): These drugs are looking like a game-changer. They help people feel better, walk further, and lose weight.
• For Heart Failure with Low Pumping Power (HFrEF): The evidence is mixed. They seem safe, but they haven't proven they stop hospitalizations yet.
• For Everyone: They seem to lower the risk of dying, but we need more specific studies to be 100% sure that this is because they fix the heart directly, rather than just helping with diabetes and weight.

In short: These drugs are a powerful new tool in the doctor's toolbox, especially for heavy hearts that are struggling to keep up. They aren't a magic cure-all yet, but they are definitely a step in the right direction.

Technical Summary

1. Problem Statement

Heart failure (HF) remains a major global health burden, with therapeutic options historically limited for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). While Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) have established cardiovascular benefits in Type 2 Diabetes (T2DM), their efficacy specifically in HF populations across all ejection fraction phenotypes (HFrEF, HFmrEF, HFpEF) has been unclear.
Prior meta-analyses were limited by the absence of recent landmark trials (e.g., SUMMIT, STEP-HFpEF, SELECT HF subgroup) and small sample sizes. There was a critical need for a comprehensive synthesis of data from both dedicated HF trials and Heart Failure subgroup analyses from large Cardiovascular Outcomes Trials (CVOTs) to determine if GLP-1 RAs reduce cardiovascular death, hospitalization, and improve functional capacity in HF patients.

2. Methodology

• Design & Registration: A prospective systematic review and meta-analysis registered with PROSPERO (CRD420261299844), conducted according to PRISMA 2020 guidelines.
• Search Strategy: A comprehensive search of PubMed, Cochrane CENTRAL, and ClinicalTrials.gov up to February 3, 2026.
• Eligibility Criteria:
  • Population: Adults (≥18 years) with established HF (any LVEF).
  • Intervention: GLP-1 RAs (semaglutide, liraglutide, tirzepatide, etc.) vs. Placebo/Usual Care.
  • Study Types: Randomized Controlled Trials (RCTs), including both dedicated HF trials and pre-specified/post-hoc HF subgroups from CVOTs.
  • Exclusions: T1DM as primary indication, observational studies, and studies without HF-specific data.
• Data Synthesis:
  • Primary Outcome: Composite of Cardiovascular (CV) death and first HF hospitalization.
  • Statistical Model: Random-effects meta-analysis using Restricted Maximum Likelihood (REML) estimation for between-study variance ($\tau^2$).
  • Adjustment: Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment for confidence intervals to ensure robust coverage with a small number of studies.
  • Heterogeneity: Assessed via $I^2$, $\tau^2$, and Cochran's Q.
  • Software: R (version 4.4) using meta and metafor packages.
• Risk of Bias: Assessed using Cochrane RoB 2 tool.

3. Key Contributions

• Scope: This is the most comprehensive synthesis to date, incorporating 14 studies (6 dedicated HF trials + 8 CVOT HF subgroup analyses) encompassing 18,558 patients.
• Granularity: It distinguishes between dedicated HF trials and CVOT subgroups, addressing the "indirectness" often present in subgroup analyses.
• Novelty: It includes the latest pivotal data from the SUMMIT (tirzepatide), STEP-HFpEF, SELECT HF, SOUL, and FLOW trials, which were missing from previous meta-analyses.
• Methodological Rigor: The use of the HKSJ adjustment and the inclusion of 95% prediction intervals provide a more realistic estimate of future study outcomes compared to standard DerSimonian-Laird methods.

4. Key Results

Primary Outcome

• Composite (CV Death + HF Hospitalization): The pooled Hazard Ratio (HR) was 0.86 (95% CI 0.73–1.01; $P=0.067$).
  • The result did not reach statistical significance under the random-effects model, though it showed a strong trend toward benefit.
  • Heterogeneity was moderate ($I^2 = 47\%$).
  • Sensitivity Analysis: Excluding the FIGHT trial (which enrolled acutely decompensated HFrEF patients and showed a harmful signal, HR 1.30) rendered the result significant (HR 0.83, $P=0.011$) with reduced heterogeneity ($I^2 = 16\%$).

Secondary Outcomes

• All-Cause Mortality: Significant reduction (HR 0.87, 95% CI 0.81–0.93; $P<0.001$).
  • Notably, heterogeneity was 0%, indicating consistent point estimates across studies.
  • Nuance: This benefit was driven primarily by CVOT subgroups. Dedicated HF trials (specifically SUMMIT) showed numerically higher mortality with tirzepatide (HR 1.25), suggesting the mortality signal may reflect broader cardiometabolic effects rather than HF-specific mechanisms.
• Major Adverse Cardiovascular Events (MACE): Significant reduction (HR 0.83, 95% CI 0.73–0.95; $P=0.019$).
• Functional Capacity & Quality of Life (HFpEF specific):
  • KCCQ-CSS: Improved by +7.4 points (95% CI 6.3–8.5), exceeding the minimal clinically important difference (MCID) of 5 points.
  • 6-Minute Walk Distance (6MWD): Improved by +17.6 meters (95% CI 13.4–21.7).
• Weight Loss: Significant reduction of -9.3 kg (95% CI -15.8 to -2.7), though with high heterogeneity ($I^2=94\%$).
• Safety: No significant increase in Serious Adverse Events (RR 0.74), though discontinuation due to adverse events was numerically higher (RR 2.27), consistent with known GI tolerability issues.

Subgroup Insights

• HF Phenotype: Benefits were most pronounced in HFpEF with obesity (supported by SUMMIT and STEP-HFpEF trials).
• Acute HFrEF: The FIGHT trial (acute decompensated HFrEF) showed a divergent, potentially harmful signal, suggesting GLP-1 RAs may not be suitable for initiation during acute decompensation.
• Agents: Semaglutide was the most studied agent (7 studies). Tirzepatide showed the largest effect size in SUMMIT but contributed to the mortality heterogeneity.

5. Significance and Clinical Implications

• Therapeutic Positioning: The study provides robust evidence supporting the use of GLP-1 RAs, particularly semaglutide and tirzepatide, for patients with HFpEF and obesity. These agents significantly improve symptoms, functional capacity, and weight, addressing the core pathophysiology of metabolic HFpEF.
• Mortality Signal: While the all-cause mortality reduction is statistically significant and consistent ($I^2=0\%$), the authors caution that this signal is driven by CVOT populations (T2DM/CVD) rather than dedicated HF trials. Future dedicated HF mortality trials are required to confirm if this is an HF-specific benefit.
• Caution in HFrEF: The lack of benefit and potential harm in the acute decompensated HFrEF setting (FIGHT trial) suggests caution in using GLP-1 RAs for acute HFrEF management.
• Guideline Impact: The findings support emerging guidelines (e.g., 2023 ESC update) that recommend GLP-1 RAs for obese HFpEF patients, filling a critical therapeutic gap where options were previously limited.

Conclusion: GLP-1 RAs offer significant benefits for symptom relief, functional capacity, and weight reduction in HFpEF with obesity, with a strong trend toward reducing cardiovascular events. While a mortality benefit is observed, its source (HF-specific vs. general cardiometabolic) requires further validation in dedicated HF mortality trials.